[{"orgOrder":0,"company":"Cellectricon","sponsor":"Delix Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Cellectricon","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cellectricon \/ Delix Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Cellectricon \/ Delix Therapeutics"},{"orgOrder":0,"company":"Dicot","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"SWEDEN","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"LIB-01","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Preclinical","graph3":"Dicot","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dicot \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Dicot \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Delix have partnered with Cellectricon to create novel assays to measure the structural and functional plasticity effects of Delix's psychoplastogen compounds using cutting-edge technologies.

                          Product Name : Undisclosed

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          February 14, 2023

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Delix Therapeutics

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : Dicot is developing the drug candidate LIB-01(formerly Libiguin), which will be a potency agent to better treat erectile dysfunction and premature ejaculation.

                          Product Name : LIB-01

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 17, 2022

                          Lead Product(s) : LIB-01

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          IFT FIRST
                          Not Confirmed
                          IFT FIRST
                          Not Confirmed

                          Details : The new patent is the second US patent for OX124. Based on Orexo's innovative scalable intranasal formulation technology, OX124 is a powerful naloxone rescue medication, designed to reverse opioid overdoses, including those from synthetic opioids, such a...

                          Product Name : OX124

                          Product Type : Controlled Substance

                          Upfront Cash : Inapplicable

                          January 27, 2021

                          Lead Product(s) : Naloxone Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank